CAPRICOR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-14
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.10%, a 8.89% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.50%, a 4.65% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.30%, a 10.26% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.90%, a 129.41% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 0.00% change from fiscal 2024.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 0.00% change from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.50%, a 15.38% increase from fiscal 2022.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.90%, a 254.55% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 4.10% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 4.50% 10-K · filed 2026-03-17 | |||
| 2025-09-30 | 4.50% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 4.50% 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 4.50% 10-K · filed 2026-03-17 | |||
| 2024-09-30 | 4.50% 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 4.50% 10-K · filed 2025-03-26 | |||
| 2023-09-30 | 4.50% 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 3.90% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 3.90% 10-K · filed 2024-03-11 | |||
| 2022-09-30 | 3.90% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 2.90% 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 1.70% 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | 1.10% 10-K · filed 2023-03-17 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | 1.50% 10-K · filed 2022-03-11 | |||
| 2020-09-30 | 1.50% 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 1.50% 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |